Pharmaceutical - Metabolics

Filter

Current filters:

Metabolics

Popular Filters

1 to 25 of 97 results

Novo Nordisk’s Saxenda gains EU approval for obesity

24-03-2015

There was good news for Danish diabetes care giant Novo Nordisk yesterday, when, late in the day, the…

DiabetesEuropeMetabolicsNovo NordiskPharmaceuticalRegulationSaxendaVictoza

Esperion shares leap on positive Phase IIb results of ETC-1002

Esperion shares leap on positive Phase IIb results of ETC-1002

18-03-2015

Emerging pharma company Esperion Therapeutics has reported positive top-line results from a Phase IIb…

Esperion TherapeuticsETC-1002MetabolicsPharmaceuticalResearch

Novo Nordisk's Saxenda achieves clinically meaningful body weight reduction in Phase IIIa SCALET trial

Novo Nordisk's Saxenda achieves clinically meaningful body weight reduction in Phase IIIa SCALET trial

09-03-2015

New data from Danish insulin giant Novo Nordisk has shown that adults with obesity or who are overweight…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Orexigen shares jump on Contrave trial interim data but FDA orders more cardio studies

Orexigen shares jump on Contrave trial interim data but FDA orders more cardio studies

04-03-2015

The US Food and Drug Administration has said it is “disappointed” by Orexigen Therapeutics’ decision…

ContraveMetabolicsNeurologicalOrexigen TherapeuticsPharmaceuticalRegulationUSA

Arena and Ildong receive marketing authorization for obesity drug Belviq in South Korea

Arena and Ildong receive marketing authorization for obesity drug Belviq in South Korea

03-02-2015

US biopharma company Arena Pharmaceuticals has received marketing authorization in South Korea for Belviq…

Arena PharmaceuticalsBelviqIldong PharmaMetabolicsPharmaceuticalRegulation

Sparse pipeline for acromegaly and gigantism treatment limiting market growth

03-02-2015

The acromegaly and gigantism treatment market will expand at a modest compound annual growth rate (CAGR)…

EuropeMarkets & MarketingMetabolicsNovartisPfizerPharmaceuticalSandostatin LARSigniforSomavertUSA

Rapid expansion forecast for global Cushing’s syndrome drug market

Rapid expansion forecast for global Cushing’s syndrome drug market

29-01-2015

The global Cushing’s syndrome (CS) treatment market will expand rapidly in value from around $179 million…

CortendoEuropeHRA PharmaKetoconazoleMarkets & MarketingMetabolicsNormoCortNovartisPharmaceuticalRare diseasesSigniforUSA

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

Novo Nordisk gets positive opinion for Saxenda from EMA’s CHMP

23-01-2015

Danish diabetes care giant Novo Nordisk revealed yesterday that the European Medicines Agency’s Committee…

DiabetesEuropeMetabolicsNovo NordiskPharmaceuticalRegulationSaxenda

Novo Nordisk’s obesity drug Saxenda approved by FDA

Novo Nordisk’s obesity drug Saxenda approved by FDA

24-12-2014

Continuing its rush of year-end drug approvals, the US Food and Drug Administration late yesterday approved…

MetabolicsNovo NordiskPharmaceuticalRegulationSaxendaUSA

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

FDA declines approval of Macrilen, issuing CRL

06-11-2014

Canadian biopharma firm AEterna Zentaris has received a Complete Response Letter from the US Food and…

Aeterna ZentarisMacrilenMetabolicsPharmaceuticalRegulationUSA

New Phase IIIa data further demonstrate benefits of liraglutide in obesity

04-11-2014

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

Orexigen earns total $100 million milestone on Contrave

Orexigen earns total $100 million milestone on Contrave

15-10-2014

US biopharma company Orexigen Therapeutics says it has earned a $70 million milestone payment from partner…

ContraveFinancialMarkets & MarketingMetabolicsOrexigen TherapeuticsPharmaceuticalTakeda PharmaceuticalUSA

Novo Nordisk establishes new obesity research unit in Seattle

Novo Nordisk establishes new obesity research unit in Seattle

26-09-2014

Danish diabetes care giant Novo Nordisk yesterday announced that the company will establish a new obesity…

ManagementMetabolicsNovo NordiskPharmaceuticalResearchSaxendaUSA

FDA advisory votes to approve Novo Nordisk diabetes drug for obesity

FDA advisory votes to approve Novo Nordisk diabetes drug for obesity

12-09-2014

There was good news for Danish diabetes care giant Novo Nordisk yesterday, when the US Food and drug…

liraglutideMetabolicsNovo NordiskPharmaceuticalRegulationSaxenda

FDA at last approves weight-management drug Contrave

FDA at last approves weight-management drug Contrave

11-09-2014

After considerable delay, the US Food and Drug Administration late yesterday finally granted approval…

Arena PharmaceuticalsBelviqContraveMetabolicsOrexigen TherapeuticsPharmaceuticalQnexaRegulationTakeda PharmaceuticalsUSAVivus

Zealand and Boehringer link up to advance novel peptide medicines

Zealand and Boehringer link up to advance novel peptide medicines

28-07-2014

Denmark’s Zealand Pharma has entered into a new global exclusive licence and R&D collaboration with…

Boehringer IngelheimCardio-vascularDenmarkFinancialGermanyLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Arena Pharma in deal with Teva unit for marketing Belviq in Israel

Arena Pharma in deal with Teva unit for marketing Belviq in Israel

21-07-2014

USA-based Arena Pharmaceuticals has entered into an exclusive marketing and supply agreement for its…

AbicArena PharmaceuticalsBelviqLicensingMetabolicsObesityPharmaceuticalRegulationRest of the WorldTeva Pharmaceutical Industries

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Zydus explores newer treatment options with its breakthrough drug Lipaglyn

Zydus explores newer treatment options with its breakthrough drug Lipaglyn

29-05-2014

Exploring newer therapeutic usage of its breakthrough drug Lipaglyn (saroglitazar), India’s Zydus Group…

DiabetesHealthHealth Medical PharmaIndiaLipaglynLipodystrophyLipodystrophyMetabolicsPharmaceuticalResearchZydus Cadila

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

1 to 25 of 97 results

Back to top